- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05056935
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus in Subjects Undergoing Elective Bowel Resection
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
-
Jiangsu
-
Xuzhou, Jiangsu, China
- General Hospital of Xuzhou Mining Group
-
Zhenjiang, Jiangsu, China
- Affiliated Hospital of Jiangsu University
-
-
Shandong
-
Qingdao, Shandong, China
- The Affiliated Hospital of Qingdao University
-
-
Shanghai
-
Shanghai, Shanghai, China
- Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine
-
-
Zhejiang
-
Ningbo, Zhejiang, China
- Ningbo First Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled to undergo an elective (non-emergent) bowel resection with or without a planned stoma via laparotomy or minimally invasive technique. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elected indication.
- Has been informed of the nature of the study (either the subject or their legal representative), agrees to its provisions, and has provided written informed consent.
Exclusion Criteria:
- <18 or >80 years of age.
- Requires emergency bowel surgery.
Has had 1 or more abdominal surgeries, excluding the current, for inflammatory bowel disease, including, but not limited to, inflammatory bowel disease (IBD), Crohn's Disease, or ulcerative colitis.
Note: This does not apply to previous surgery such as hernia repair unrelated to IBD.
- American Society of Anesthesiologists (ASA) Class 4 or 5.
- Insulin dependent diabetes mellitus.
- Known inability to take the study drug orally (i.e. complete small bowel obstruction).
Has contraindications or potential risk factors to taking tranexamic acid (TXA). These include subjects with:
- Known sensitivity to tranexamic acid (TXA);
- Recent craniotomy (past 30 days);
- Active cerebrovascular bleed;
- Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome);
- Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction, or
- Continuing use of a combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch, or vaginal ring).
- Known allergic reaction to polyethylene glycol (PEG) 4000 powder, combination formulation of polyethylene glycol (PEG) and electrolyte powder, polyethylene glycol (PEG) 3350 solution and glucose formulation.
Has the following risk factors for thromboembolic disease:
Known medical history of congenital or acquired thrombophilia such as, but not limited to patients with:
- Sickle cell disease;
- Nephrotic syndrome;
- Factor V Leiden;
- Prothrombin gene mutation;
- Protein C or S deficiency;
- Antithrombin III deficiency;
- Antiphospholipid syndrome.
- Stage IV malignant neoplasm;
- Neurologic paresis, partial paralysis, or paralysis;
- Pacemaker;
- History of pulmonary embolism, deep vein thrombosis, cerebrovascular accident, or rental venous/arterial occlusion;
- History of or current seizure disorder.
- Patients with myeloproliferative disorders.
- Body Mass Index (BMI) >40.
- Any other condition that, in the opinion of the Investigator, would preclude the subject from being an appropriate candidate for the study, including severe renal or hepatic impairment.
- Planned treatment with alvimopan (Entereg®) during study participation period.
- Received any other investigational therapy within 4 weeks prior to Randomization
- Chronic opioid usage, defined by the American Pain Society as daily or near-daily use of opioids for at least 90 days.
- Female subjects of childbearing potential with a positive urine or serum pregnancy test or who are not taking (or not willing to take) acceptable birth control measures (abstinence, intrauterine devices, contraceptive implants or barrier methods) through Day 30. Additionally, those women who are lactating and insist on breast feeding within 5 days of the last dose of study drug.
- Known history of radiation enteritis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
placebo
|
A total of 700 mL of placebo will be administered orally as a split dose before surgery.
|
Experimental: LB1148
active
|
A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to reach GI-2
Time Frame: within 14 days after surgery
|
• GI-2 is defined as the toleration of solid food and first bowel movement.
|
within 14 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to reach GI-3
Time Frame: within 14 days after surgery
|
• GI-3 is defined as the toleration of solid food and either first flatus or bowel movement.
|
within 14 days after surgery
|
Nausea Verbal Rating Scoring Scale
Time Frame: within 14 days after surgery
|
• To assess the nausea and ability to tolerate food
|
within 14 days after surgery
|
Number of days in the hospital
Time Frame: within 14 days after surgery
|
• Length of Stay (number of days in the hospital, evaluated in hours) will be measured by time to
|
within 14 days after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LBS-POI-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ileus
-
Assiut UniversityRecruitingPostoperative IleusEgypt
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedPostoperative Ileus | Gynecologic Disease | Paralytic IleusTurkey
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenRecruitingPostoperative IleusBelgium
-
West China HospitalCompletedPostoperative IleusChina
-
Hadassah Medical OrganizationCompleted
-
li xiongUnknown
-
Jinling Hospital, ChinaCompletedPostoperative IleusChina
-
Services Hospital, LahoreCompletedPostoperative IleusPakistan
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenCompletedPostoperative IleusBelgium
-
Gabriele Baldini, MD, MSc, Assistant ProfessorCompleted
Clinical Trials on LB1148
-
Palisade BioRecruitingIleus | Post-Operative AdhesionsUnited States
-
Palisade BioActive, not recruitingIleus | Gastro-Intestinal DisorderUnited States
-
Ronald Hurst, MD, FACSCompletedIleus | AdhesionsUnited States
-
Leading BioSciences, IncTerminatedSeptic ShockUnited States, Canada
-
Leading BioSciences, IncWithdrawnCOVID-19 | Covid19 | Coronavirus Disease 2019 | COVID-19 Pneumonia